US/UK/Canada

Share

Quotes

The goal is to attract a licensing partner after completing phase I/II in order to continue the development. An alternative scenario is to find a partner before entering clinical studies, based on a precise development plan
Suzanne Kilany, CRD Aptahem
It is a very exciting result for any drug candidate to trigger a protein like Pentraxin-3 with such a broad spectrum of effects
Luiza Jedlina, CSO Aptahem
Aptahem is currently focusing on sepsis, but there is possibility for potentially expanding the indication. At present, no such decision has been made, but we are not ruling it out
Mikael Lindstam, CEO Aptahem
Pick a time period -
Tags ( Active)

Aptahem to Participate at IOPC 2026 in Athens

Aptahem AB (publ), a clinical-stage biotech company listed on the Spotlight Stock Market that develops RNA-based treatments for acute thrombo-inflammatory conditions, today announced that CEO Mikael Lindstam and CMC Director Thomas Rupp will participate at the International Oligonucleotides and Peptides Conference, IOPC 2026, taking place June 9–11, 2026, in Athens, Greece.IOPC 2026 brings together leading stakeholders from industry, academia, clinical development and the broader life science ecosystem within oligonucleotides, peptides and related therapeutic technologies. Aptahem’s

Newsletter May 2026

World Sepsis Congress Highlights the Great Need for Apta-1Dear shareholders, In mid-April, the World Sepsis Congress convened leading experts from around the world, including WHO Director-General Dr. Tedros Adhanom Ghebreyesus. In his opening remarks, he highlighted the staggering scale of the problem : nearly 50 million people are affected by sepsis every year, and approximately 11 million die from it. He then added a sentence that captured the urgency of the issue with striking clarity: “Nobody should die while

Newsletter December 2025

Toward a New Trajectory: The CEO’s Reflections on Aptahem’s 2025A Year of Transformation, Deepening Capabilities, and Global Positioning Looking back at 2025, one thing is clear: this was the year when Aptahem truly began its transition from a promising Nordic biotech company into an organization with international presence, rigor, and ambition. We executed one of the most comprehensive advancement cycles in our history - scientifically, regulatorily, and strategically - with a single goal in mind: to bring Apta-1 to patients lacking effective treatment options. This progress unfolded

Aptahem receives patent protection in China for patent family 2

Aptahem AB (publ) announces today that the company has received patent protection in China for patent family 2 from the Chinese Patent Office.With the approval in China of patent application 2018800643106, the protection of the company’s drug candidate Apta-1 within patent family 2 in China, Chinese Patent No. 111386121, is valid until the end of 2038. For further information: Aptahem ABMikael Lindstam, CEOTel: +46 (0)766-33 36 99E-mail: ml@aptahem.com About Aptahem Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the

Aptahem’s webinar ”Strategic Direction and Planned US Listing” now available

Aptahem hosted a webinar where CEO Mikael Lindstam provided an overview of Aptahem’s strategic direction, ongoing preparations for a planned U.S. listing, and recent key regulatory developments.The webinar is available via the link below: https://gumlet.tv/watch/6902846960d267cdc081c34f/ For further information: Aptahem ABMikael Lindstam, CEOTel: +46 (0)766-33 36 99Epost: ml@aptahem.com About Aptahem Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a

Aptahem Announces English-Language Webinar on Strategic Direction and Planned U.S. Listing

Aptahem AB (publ) (“Aptahem” or the “Company”), a clinical-stage biotech company listed on the Spotlight Stock Market that develops RNA-based treatments for acute thrombo-inflammatory conditions, today announces that it will host an English-language investor webinar on Wednesday, October 29, 2025, at 3:00 p.m. CEST.The purpose of the webinar is to provide an overview of Aptahem’s strategic direction, ongoing preparations for a planned U.S. listing, and recent key regulatory developments. The English-language event follows the Company’s Swedish webinar held on September 22 and is intended to

Newsletter October 2025

From Global Statistics to Personal Stories by Madonna: Why Our Work at Aptahem MattersDear shareholders and stakeholders! Last week, the World Health Organization published a new report on the spread of drug resistance. While this does not directly affect Aptahem in the short term, I believe it is relevant for you as shareholders to understand some of the underlying drivers behind a megatrend that, in my view, will continue to increase the need for new and better treatments for sepsis — a role we hope Apta-1 will fulfill. In addition, there have recently been a few notable cases of

Aptahem moves forward with focus on U.S. listing strategy, regulatory progress, and partner engagement following outcome of rights issue

Aptahem AB (publ) (“Aptahem” or the “Company”), a clinical-stage biotech company listed on the Spotlight Stock Market that develops RNA-based treatments for acute thrombo-inflammatory conditions, today announces that, following the preliminary outcome of its rights issue, the Company will continue to pursue its strategic decision to move toward a U.S. listing, with a clear focus on operational efficiency.As communicated on 26 August 2025, Aptahem has initiated a process to become listed on a U.S. stock exchange, with the goal of achieving a market valuation that better reflects the Company’

Aptahem receives Notice of Allowance in China for patent family 2

Aptahem AB (publ) announces today that the company has received a Notice of Allowance in China of the patent application no 2018800643106 entitled A nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties.The notice of allowance is a formal communication from the patent authority in which it indicates that the patent application has reached the status where it is allowed for issuance as a patent. When issued, the patent will be valid until, and including, 2038. CEO Mikael Lindstam comments: ”The fact that we have now received notification that

Aptahem Outlines Ongoing Preparations for Planned U.S. Listing and Announces Webinar Invitation

Aptahem AB (publ) (“Aptahem” or the “Company”), a clinical-stage biotech company listed on the Spotlight Stock Market that develops RNA-based treatments for acute thrombo-inflammatory conditions, today provides an update on the Company’s preparations for a planned U.S. listing and announces an upcoming webinar on Monday, September 22, to which all interested parties are invited (see details below).The initiative to pursue a U.S. listing is part of the strategic direction announced on August 26, aimed at achieving a market valuation that more accurately reflects the Company’s scientific

Aptahem is applying to the FDA's CNPV pilot program for accelerated drug review

Aptahem AB (publ), a biotech company developing RNA-based treatments for acute thrombo-inflammatory conditions, announces that the company has submitted an application for participation in the U.S. Food and Drug Administration’s (FDA) Commissioner’s National Priority Voucher (CNPV) Pilot Program – “Accelerated Drug Review for Companies Supporting U.S. National Interests.” The application is made as a next step after Aptahem’s previous application to FDA PreCheck on August 13, 2025. It complements the company’s application to FDA PreCheck and strengthens the U.S.-focused regulatory strategy.

Newsletter No 2, August 2025

Follow-up to the memo on Aptahem's strategic direction towards a US listingDear shareholders and stakeholders! I would like to provide some more information about the background to Aptahem's latest press release. We have announced that the company is initiating a strategic process with the aim of conducting a listing in the US to create better conditions to finance a planned phase 2 study with Apta-1 and build long-term value in the portfolio. With this newsletter, I would like to clarify how the US track, a strong phase 2 approach and potential FDA programs can contribute to shareholder

Aptahem announces Strategic Direction for U.S. Listing to Enable Phase 2 Study and build portfolio assets value

Aptahem AB (publ) (“Aptahem” or the “Company”), currently listed on Spotlight Stock Market, today announces that the Company has initiated a strategic process to pursue a listing of the Company’s shares on a U.S. stock exchange, such as Nasdaq in the United States. The purpose of this strategic initiative is to create improved conditions for financing the Company’s planned Phase 2 clinical trial with its drug candidate Apta-1 – a program with significant potential that requires substantial capital resources.In ongoing discussions with investors and partners, the Company has identified that

Aptahem files provisional patent application in USA for new indications for Apta-1

Aptahem AB (publ), a biotech company developing treatments for patients suffering from acute inflammatory diseases, today announces that the company has received patent pending status through a provisional patent application in the USA. The application aims to protect the company's lead RNA aptamer Apta-1 in new indication areas, based on detailed evaluation of data generated from previous studies with Apta-1.These groundbreaking new insights are based on the detailed evaluation of data generated from Apta-1 by the Company’s Co-Founder and CSO Dr. Luiza Jedlina. Dr. Jedlina has identified

Aptahem Applies to FDA PreCheck Program – Strategic Step Toward Faster, Higher-Quality Drug Manufacturing

Aptahem AB (publ), a biotech company developing RNA-based treatments for severe inflammatory conditions, is strengthening its position as a leader in RNA-based therapeutics by applying to the FDA PreCheck Program, the agency’s new initiative to accelerate and streamline inspections of drug manufacturing.The program is reserved for companies with a proven track record of high-quality, GMP-compliant operations, offering prioritized inspections and regulatory transparency. For Aptahem, participation means: · Faster regulatory pathway for production of Apta-1, our breakthrough RNA aptamer

Aptahem receives strong interest in partnership from a European pharmaceutical company

Aptahem AB (publ), a biotechnology company developing RNA-based therapies for serious inflammatory conditions, announces today that the company has received a formal expression of interest from a well-reputed European pharmaceutical company with interest in Aptahem's innovation platform.After an extended period of constructive dialogue, the European company has expressed in writing a strong interest in pursuing discussions and entering into a potential partnership with Aptahem. The expressed interest relates to the company's innovative lead candidate Apta-1 with regard mainly to anti-

Aptahem Initiates Strategic Collaboration with Hongene Biotech to further reduce Manufacturing Costs and Enhance Sustainability for Lead Drug Candidate Apta-1

Aptahem AB (publ), a biotech company developing RNA-based treatments for severe inflammatory conditions, announces a strategic collaboration with Hongene Biotech, a global leader in RNA and Oligo manufacturing with production facilities in both China and Hungary (from 2027). The partnership aims to explore and implement new, cutting-edge production methods that significantly reduce manufacturing costs and enhance sustainability for Aptahem’s lead candidate, Apta-1.Through the adoption of innovative process systems, Aptahem and Hongene expect to initially considerable cut the cost of goods (

BioStock Article: Aptahem reports growing buzz around Apta-1

Malmö-based Aptahem recently released detailed plans of their upcoming phase II study with candidate Apta-1, set to prove its multifaceted potential and optimise future market opportunities. Meanwhile, the company has intensified partnership discussions, noting increased interest from major players following BIO-Europe in Milan.Read the full article at Aptahem’s website . For further information: Aptahem ABMikael Lindstam, CEOTel: +46 (0)766-33 36 99E-mail: ml@aptahem.com About Aptahem Aptahem AB (APTA) is a clinical stage biotechnology

Mangold Insight’s CEO Interview follows up on previous interview from BIO Europe Spring

Mangold Insight recently published an interview with Aptahem’s CEO Mikael Lindstam. The interview follows up on the video interview from BIO Europe Spring in Milan and on the latest press release announcing the synopsis for the planned patient study with Apta-1. The interview is available on Mangold Insight’s website  and on www.aptahem.com.The interview is written in English. For further information: Aptahem ABMikael Lindstam, CEOTel: +46 (0)766-33 36 99E-mail: ml@aptahem.com About Aptahem Aptahem AB (

Aptahem presents plan for upcoming patient study

Aptahem AB (publ) announces today a synopsis for the upcoming clinical phase 2 study of the drug candidate Apta-1. The study will be performed as an open, single arm phase 2 study to evaluate the efficacy and safety of Apta-1, an innovative immunomodulatory and antithrombotic drug candidate, in patients with acute urogenital and renal conditions.The study will be performed as a Proof-of-Concept study in adult patients diagnosed with various types of acute urogenital disorders including acute kidney disorders. Within these disorders, there are several indications with orphan status, an area

Newsletter March 2025

CEO commentsWe have now entered 2025 with high energy and a clear focus on driving Aptahem forward. The interest in RNA-related medicines continues to grow and we see increased demand for innovative solutions in this segment. This momentum benefits us and our technology, creating solid conditions for future partnership discussions and strategic meetings. In addition, Aptahem's election committee has proposed a new addition to the board ahead of the upcoming annual general meeting. Strengthening the board's strategic expertise has been prioritized as the company prepares for the upcoming

Aptahem receives patent protection in South Korea for patent family 2

Aptahem AB (publ) announces today that the company has received patent protection (Notice of Patent Grant) in South Korea for the patent application no 10-2020-7007266 entitled A nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties.With the approval in South Korea of patent application 10-2020-7007266, the protection of the company’s drug candidate Apta-1 within patent family 2 in South Korea is valid until the end of 2038. CEO Mikael Lindstam comments “I am pleased to announce that one of the few remaining patent applications has now been

Aptahem's Scientific Manuscript now Published in the British Journal of Pharmacology

Aptahem announced on 10 September 2024 that their scientific manuscript had been accepted for publication in the British Journal of Pharmacology (BJP). On the 9th December 2024, the article has been published.Read the article, titled “Antithrombotic but not anticoagulant activity of the thrombin-binding RNA aptamer Apta-1”, via this link . The article describes the results of the preclinical and mechanistic studies that have been performed by Aptahem and in a collaboration during several years with Örebro University. The study

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe